Competitor Analysis: Cancer Vaccines

Date: March 24, 2014
Pages: 179
US$ 1,112.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CD6671E2188EN

Download PDF Leaflet

Competitor Analysis: Cancer Vaccines
The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Projects are listed according to their main antigenic constituents: peptides, recombinant proteins, idiotype antibody, DNA (plasmid, expression vector), RNA, virus-like particles (VLP), dendritic cells, tumor cells (tumor cell lines), microorganism-based and others.

Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major pharmaceutical markets with combined 2013 sales of US$ 2,385 mln. Peptides and proteins make out 43% of clinical stage cancer vaccines, followed by dendritic cell and tumor cell (line)-based cancer vaccines with each contributing 15% to the clinical cancer vaccine pipeline. DNA- and RNA-based cancer vaccines maked out 17% of the clinical portfolio.

The report includes a compilation of currently active projects in research and development for prophylaxis and therapy of cancer. In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced."

Peptide-based Cancer Vaccines
Protein-based Cancer Vaccines
Idiotype Antibody-based Cancer Vaccines
DNA-based Cancer Vaccines: naked and virally vectored
RNA-based Cancer Vaccines
Virus-Like Particle (VLP)-based Cancer Vaccines
Dendritic Cell-based Cancer Vaccines
Tumor Cell and Tumor Cell Line – based Cancer Vaccines
Microorganism-based Cancer Vaccines
Other and Not Defined Cancer Vaccines


Skip to top

Competitor Analysis: HPV Vaccines US$ 170.00 May, 2010 · 18 pages
Competitor Analysis: Malaria Vaccines & Therapeutics US$ 390.00 Aug, 2012 · 64 pages
Competitor Analysis: RSV Vaccines and Therapeutics US$ 315.00 Jun, 2012 · 30 pages
Competitor Analysis: CMV Vaccines & Therapeutics US$ 247.00 Aug, 2012 · 23 pages

Ask Your Question

Competitor Analysis: Cancer Vaccines
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: